HANXBIO-B(03378) collaborates with TwinEdge Bioscience on AI drug research and development.

HANXBIO-B(03378) announced that the company has signed a cooperation agreement with TwinEdge Bioscience, a cutting-edge biotechnology company based in Switzerland specializing in unique computational biology technologies, to conduct research on their collaborative project. The two parties will utilize artificial intelligence technology to conduct translational medical research on HX009, a core bispecific antibody therapy candidate of Hansa Biotech. According to the agreement, TwinEdge Bioscience will develop personalized "digital twins" or "avatars" models based on a series of xenograft patient-derived xenograft (PDX) mouse models of diffuse large B-cell lymphoma (DLBCL) using its unique AI models and tools. The establishment of these digital twins has made preliminary progress, laying the foundation for integrating molecular and dose-response data into simulation mechanisms. This collaboration aims to further elucidate the mechanism of action of HX009, simulate its potential clinical manifestations in lymphoma patients, and explore the applicability and relevance of this mechanism in DLBCL. Traditional preclinical testing results may limit the in-depth exploration of early drug efficacy and individual differences in trial participants. This collaboration leverages AI digital twin technology to conduct simulation calculations on thousands of simulated patients to explore the heterogeneity within the lymphoma patient population and patterns of response related to biomarkers. The implementation of this collaboration may improve the patient selection scheme of the company, strengthen the early translational medical evidence of HX009, and help optimize its subsequent clinical pathway planning, accelerating the clinical development process.